TrialBMC cancer2026

Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial.

Hao Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.